Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) have earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus price target of $30.00 for the company and are predicting that the company will post ($0.59) earnings per share for the current quarter, according to Zacks. Zacks has also given Jounce Therapeutics an industry rank of 112 out of 265 based on the ratings given to its competitors.

Several research firms have commented on JNCE. Zacks Investment Research downgraded shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Robert W. Baird reaffirmed a “buy” rating and issued a $30.00 target price on shares of Jounce Therapeutics in a research note on Friday, November 10th. Finally, J P Morgan Chase & Co set a $28.00 target price on shares of Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th.

Several hedge funds and other institutional investors have recently modified their holdings of JNCE. Macquarie Group Ltd. purchased a new position in shares of Jounce Therapeutics in the third quarter worth $124,000. American International Group Inc. increased its stake in shares of Jounce Therapeutics by 132.2% in the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after buying an additional 5,442 shares during the period. Teachers Advisors LLC increased its stake in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after buying an additional 2,347 shares during the period. Ark Investment Management LLC increased its stake in shares of Jounce Therapeutics by 558.9% in the second quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after buying an additional 10,121 shares during the period. Finally, Nationwide Fund Advisors increased its stake in shares of Jounce Therapeutics by 203.3% in the second quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after buying an additional 8,007 shares during the period. 47.55% of the stock is currently owned by institutional investors.

Jounce Therapeutics (NASDAQ:JNCE) opened at $13.71 on Wednesday. Jounce Therapeutics has a one year low of $11.05 and a one year high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.12. The firm had revenue of $18.10 million for the quarter, compared to the consensus estimate of $20.00 million. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. equities research analysts anticipate that Jounce Therapeutics will post -0.86 earnings per share for the current year.

WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/13/brokerages-anticipate-jounce-therapeutics-inc-jnce-to-post-0-59-earnings-per-share.html.

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.